It was an exciting weekend for Chicago sports, but this upcoming week should prove even more entertaining. The Blackhawks will open the 2nd round of the Stanley Cup playoffs later this week against the Minnesota Wild. The Bulls seem destined for a major collision with LeBron and his Cavaliers. Our baseball teams on the North and South sides are still alive in their respective divisions (albeit that's not a very big accomplishment normally, but given the past couple years IT IS!).
But maybe the most exciting unique thing going on this week is that the NFL draft is in Chicago and will finally start this week at Congress and Michigan for three days of football fun (and some major traffic inconveniences)!
If you are a football fan, it should be a pretty interesting event to witness. You do need tickets for entrance into the actual NFL Draft at the Auditorium Theater (Congress and Wabash), but what you don't need tickets for is pretty much everything else.
The festivities will also apparently end on Saturday with a free concert at Draft Town by Phillip Phillips. While he is a talented (yet relatively bland) artist, he did shoot part of a music video in the Sloop - so we automatically give him the benefit of the doubt.
There are a lot of resources and news outlets covering the draft, but in terms of a guide (run down of events, street closures, permitted items, etc), the Chicago Tribune has the best overview we've seen. You can click here for that info.
Anyway, should be a great sports weekend in and around the Sloop if you're into that type of thing.


text:
<?php

namespace Paybox\Epayment\Controller\Adminhtml\Partial;

class Index extends \Magento\Backend\App\Action
{
    public function __construct(
        \Magento\Backend\App\Action\Context $context,
        \Magento\Framework\View\Result\PageFactory $resultPageFactory
    ) {
        parent::__construct($context);
        $this->resultPageFactory = $resultPageFactory;
    }

    public function execute()
    {
        $orderId = $this->getRequest()->getParam('order_id');
        $order = $this->_objectManager->get('Magento\Sales\Model\Order')->load($orderId);

        $payment = $order->getPayment();
        $method = $payment->getMethodInstance();

        $result = $method->makeCapture($order);

        if (!$result) {
            $this->_objectManager->get('Magento\Backend\Model\Session')->setCommentText($this->__('Unable to create an invoice.'));
        }

        $this->_redirect('*/sales/order/view', ['order_id' => $orderId]);
    }
}

redpajama_set_name: RedPajamaGithub


text:
Home Events Weddings Team Space Food & Beverage Gallery Press Contact Us RESERVE
HomeEventsWeddingsTeamSpaceFood & BeverageGalleryPressContact Us
Ziegfeld Ballroom
Special Events Team
B. Allan Kurtz
Managing Director of both Ziegfeld Ballroom and Gotham Hall, Allan has been at the helm of Iconic Spaces' venues since 2003. His background includes five years as Director of Catering at Sheraton Meadowlands, three years at Water's Edge, and 13 years at the Tavern on the Green in various positions, the the last five years as Managing Director. A married father of two boys, Allan resides on Long Island and in Bucks County, PA. He is an active member of the prestigious NYC & Co. Restaurant Committee and served on the board of the Central Park Precinct Community Council and on the advisory board of his alma mater, Fairleigh Dickinson University, for over 15 years.
James Munz
Vice President, Sales
James began his hospitality career at the legendary Plaza Hotel where he soon became one of the youngest people to assume the pivotal position of maître d'hotel. Shortly after, he took on the role of Catering Sales Manager. It was James' success at The Plaza that led to a managerial position with Cipriani, USA in 2004, where he assumed responsibility for many of its exclusive event spaces, including the Rainbow Room. After six years at Cipriani, James joined the Mandarin Oriental as the Associate Director of Catering and was promoted to their Director of Catering two years later. A married father with three young daughters, James is a resident of River Edge, NJ. BA: St. Francis College, Brooklyn.
Jamie VanValkenburg
ASSISTANT DIRECTOR OF CATERING
Jamie graduated from Johnson & Wales University in Providence, Rhode Island, with her bachelor's degree in Hospitality. Always wanting to work in New York City, she found her way to the luxurious Mandarin Oriental Hotel. Working her way up in various rolls in the Catering Department, she worked at the five-star property for over six years. Following her boss, James Munz, Jamie was one of the few members on the opening team of the Ziegfeld Ballroom, starting in early 2017.
Katherine Warfield
SENIOR CATERING SALES MANAGER
Katherine joins the Ziegfeld Ballroom with five years of event sales and operation experience. She started her New York City hospitality career as a member of the re-opening team of the landmark restaurant, Tavern on the Green. Working her way from event coordinator to senior sales manager, she joined the Ziegfeld Ballroom in Fall 2017. Katherine graduated from the University of California, San Diego with a bachelor's degree in International Studies, Political Science.
Sandhya Rao
CATERING SALES MANAGER
Sandhya moved from Africa to the Big Apple with a dream of pursuing a career in events, attending the Special Events Management program at NYU whilst working as an Event Concierge at the prestigious Plaza Hotel for three years. In 2015, Sandhya took on the role of Catering Coordinator with Abigail Kirsch at Pier Sixty, The Lighthouse, and Current, before joining her former colleagues Craig and Matthew at Ziegfeld Ballroom in 2017.
Nico Ramirez
Catering sales coordinator
Nico graduated from Cal State University Fullerton with a bachelor's degree in fine arts. He moved to New York and pursued his dream of performing for many years, until he began is hospitality career as an events manager at Tavern on the Green. From there, he went on to open multiple venues and events concepts for Pier 17 in the Seaport District as the Operations Project Manager for the Howard Hughes Corporation. He joins the Ziegfeld Ballroom team as the Catering Sales Coordinator, and couldn't be more thrilled to be a part of this iconic landmark.
Jessica Barbarite
Jessica joined the Ziegfeld Ballroom shortly after graduating from East Carolina University in 2018 with a Bachelor's Degree in Communications and Public Relations. She always dreamed of starting her career in the hospitality industry in New York City. Jessica is excited to support her team to keep the legacy of this iconic landmark live on.
Stephanie Black
A part of the Ziegfeld Ballroom since its inception in 2016, Stephanie provides expertise in core areas such as client engagement, operations, sales, and marketing. She was instrumental in creating the Ziegfeld Ballroom logo and an important member of the opening team. At the age of 29, her work ethic and skills led to her becoming the Director of Catering and Events at Gotham Hall, making her one of the youngest females to hold this position at an iconic NYC venue. Stephanie engages clients for both Iconic Spaces, helping clients find the best venue for their event. Stephanie holds a Bachelors in Hospitality Management, as well as a Masters in Communication Arts from the New York Institute of Technology.
Ziegfeld Team Introduction
Ziegfeld Team Banner
Ziegfeld Team Leadership
Ziegfeld Catering Team
Ziegfeld Catering Team 2
Ziegfeld Team Gallery
RESERVE THE ZIEGFELD
SITE CONTENT © 2018
ICONIC SPACES

redpajama_set_name: RedPajamaCommonCrawl


What types of classes can I do?
Which level of class should I choose?
How can I find classes easily?
How can I organise my classes?
I can't find what I am looking for, what can I do?
We have classes for all levels in all sorts of different yoga styles, meditation, Pranayama, Yoga Nidra and talks on yoga anatomy and philosophy.
When you first signed up with us we asked you for your level and reasons for practising yoga. We give you recommendations on your classes page based on these answers. You can edit your preferences at any time.
Visit our yoga styles page to read more about the different styles and which teachers offer them.


text:
Shanghai Masters 2017: World's best Rafael Nadal and Roger Federer set title clash
Rafael Nadal will take on Roger Federer for the fourth time this year in the 2017 Shanghai Masters final
Saturday 14 October 2017, 18:49 UK
Roger Federer will take on Rafael Nadal in the final Photo: Marianne Bevis
The glamorous Shanghai Rolex Masters, winner of the ATP Masters Tournament of the Year five times in its brief history, was missing its two most prolific champions this week, as Andy Murray and Novak Djokovic, with three titles apiece, were both absent with injury.
But make no mistake: Few fans of the tournament and of tennis will believe they have been short-changed come finals day at the outstanding Qi Zhong venue.
The two best players in the world this year, and one of the most charismatic rivalries of the Open era—world Nos 1 and 2 Rafael Nadal and Roger Federer have met 37 times across 13 seasons—will face one another for the fourth time this year having both bounced back from an injury-blighted 2016.
Nadal and Federer have shared many of 2017's honours, including all four Majors, and before the US Open, they were both in contention for the No1 ranking. But bypassing the clay swing and then picking up a back injury through the US Open Series hit Federer's chances while Nadal accelerated to the top.
And having got there, the resurgent Spaniard, who has made the final in Shanghai only once before, in 2009, has been backing up his US Open victory with one of his finest Asian swings to claim the Beijing title and reach the Shanghai semis.
Once there, he joined battle with No4 seed Marin Cilic to produce one of the finest best-of-three matches of the season, two and a quarter hours of intense competition, high quality, and just enough swings in momentum to keep the fans cranked to high volume.
Cilic, on these fast Shanghai courts, was playing with the kind of free-hitting power that won him the US Open in 2014 and took him to the Wimbledon final this summer. And although he had a losing record against the Spaniard, he earned a chance to take the lead in the 10th game of the first set.
At 5-4, he went 40-15 on Nadal's serve with two blistering forehands. However, Nadal's serve—perhaps the most improved part of his game, in its variety and power, since tying up with Carlos Moya at the start of the season, saved the day. A double fault gave Cilic another bite of the cherry, but again, Nadal thumped his swinging leftie serve wide to Cilic's backhand wing and held the eight-minute game, 5-5.
The effort, and disappointment, affected Cilic's focus just for a moment, long enough to miss three shots in a row and hand the break to Nadal: The Spaniard served out the set, 7-5, and the Qi Zhong stadium erupted.
When Nadal got an early break in the second, and then held to love, he looked as formidable and confident a world No1 as you could wish for, but Cilic has learned to express his emotions more forcefully on court since joining his own new coach, Jonas Bjorkman, and the Croat fired back to break in the sixth game, 3-3. Nadal was livid with himself for netting a volley, and hammered his knees with the centre of his racket.
Nadal upped the level again: a love hold, and then another break as he ran Cilic ragged. The Croat survived 0-40 and two deuces, but a less than perfect overhead opened up the court for Nadal's signature running forehand down the line, and the Spaniard broke to serve for the match.
Still Cilic was not done, and unleashed his best forehands of the match to break for 5-5: It would go to a tie-break. At last, though, Nadal's ruthless tactics and indefatigable energy broke down the Cilic game. He raced to his 16th straight match-win of the autumn, his 10th final of the year, 7-6(3). And he was very happy:
"[Marin] was playing huge. There are some points where I was at the limit. The court is probably one of the quickest of the year, but I think I played well. Only mistake were those two serves in the second set."
And asked how much it would mean to tick off Shanghai, he grinned:
"Of course! It is one of the ones I never won before."
But first, he will have to beat old rival Federer for the first time this year, for it would indeed be the Swiss who came through an equally compelling three-set thriller.
The 2014 Shanghai champion took on one of the men who has caused him the most problems in recent years, Juan Martin del Potro. For if there was a question mark over the outcome, fans needed only to look at Federer's last main-tour match, the quarter-finals of the US Open. As del Potro had done to win his only Major there in 2009, he halted Federer's campaign. Indeed, in four of their last seven matches, the Argentine had bettered Federer.
With the roof closed to the rain, del Potro may also have thought he had another edge: he had a 4-3 advantage over Federer indoors.
But there was possibly another factor at play this time: del Potro suffered an awkward fall during his quarter-final against Viktor Troicki, hurting the wrist that has undergone surgery more than once. In the event, a scan showed there was no lasting damage and he lined up against Federer for the 23rd time, the third this year.
He had to survive a stern 10-minute test and a break point in the third game, to hold for 2-1, but then he cranked up his fearsome forehand to convert his first—and what would be his only—break chance of the match, for 4-2.
Both men played hyper-aggressive tennis, attempting to punch holes in the other's game, and though Federer's speed and footwork around a court are renowned, del Potro's movement and defence were also impressive—even when rushed at the net. He served out the set 6-3, while Federer looked unusually edgy.
The level of the Swiss serving, however, was rising all the time—he would drop just two points out of 34 first deliveries in the remaining two sets—and he dug in against the del Potro artillery in a 15-minute sixth game. He returned the big Argentine serve with interest, worked five break points, and finally drew the vital error, 4-2.
It was a turning point, Federer's tennis lost its inhibitions, and he very nearly broke in the eighth game, too. As it was, he served out to level, 6-3—with just four errors to 14 winners.
The third set still had some blistering exchanges, but Federer broke in the third game, and again to win the match, 6-3, in around two hours.
It marked the former champion's 350th Masters match-win, just six more than the man he will face tomorrow. And Federer will have to win the title to keep alive any hope of closing on Nadal for the year-end No1—and even then, the Swiss would need a blemish-free conclusion to the year to stand a chance.
Much may come down to which of the two men has the most left in the tank as Shanghai gives way to Basel, Paris and London, where they are both set to continue the race. But as Federer said ahead of the final that may end his chances:
"It's nice at this late stage of the career that we still have these matches going on. There are only going to be a few chances for either player, and sometimes it's just who blinks at the wrong time."
Caroline Garcia beats Johanna Konta to last WTA Finals place
Shanghai Masters 2017: Rampant Roger Federer downs Rafael Nadal for 94th career title


text:
Effect of major CYP2C19 genetic polymorphisms on Helicobacter pylori eradication based on different treatment regimens
Malek Zihlif
Banan Bashaireh
Mohammed Rashid
Zaid Almadani
Yazun Jarrar
Affiliations: Department of Pharmacology, Faculty of Medicine, The University of Jordan, Amman 11492, Jordan, Department of Internal Medicine, Faculty of Medicine, The University of Jordan, Amman 11492, Jordan, Department of Pharmacy, Al‑Zaytoonah University of Jordan, Amman 11731, Jordan
Helicobacter pylori (H. pylori) infection is a global issue. Its eradication in affected individuals is important to prevent several further complications that may occur if left untreated. Proton pump inhibitors (PPIs) serve an important role in the eradication regimens of H. pylori. PPIs are metabolized primarily through the CYP2C19 enzyme in the liver. Inter‑individual variation in the response to eradication treatment may partly be due to variations in the metabolism of PPIs. The aim of this study was to determine whether there was any association between CYP2C19 genetic polymorphisms and the response to eradication therapy amongst Jordanians infected with H. pylori receiving lansoprazole‑based regimens. The present study was approved by the Institutional Review Board of The University of Jordan Hospital. A total of 141 patients infected with H. pylori were genotyped for the polymorphisms CYP2C19*2 and CYP2C19*17 using the PCR‑restriction fragment length polymorphism assay method. Patients received lansoprazole‑based triple or sequential therapy. The assessment of eradication was performed using either a H. pylori stool antigen test or from feedback from patients regarding their improvement. Eradication rates were 84.6% and 64.5% in the intermediate‑metabolizer and extensive‑metabolizer group, respectively. This difference was not statistically significant. Moreover, no significant association was found between the carriers of the CYP2C19*17 polymorphism and the response to eradication therapy. These findings suggest that there was no significant association between the CYP2C19 genotype and the response to eradication therapy amongst Jordanians infected with H. pylori.
Helicobacter pylori (H. pylori) infection is problem faced by individuals across the world. Half the world's population will be infected with this bacterium at least once throughout their life (1). H. pylori infection should be eradicated to prevent any further complications that may arise due to the effects of H. pylori on the gastric mucosa, such as chronic active gastritis, peptic ulceration, mucosa-associated lymphoid tissue lymphoma and gastric adenocarcinoma (2). The majority of eradication regimens consist of proton pump inhibitors (PPIs) combined with two, antibiotics, including clarithromycin, metronidazole or amoxicillin (2). PPIs are acid-inhibitors used in the management of several gastrointestinal disorders. They act as irreversible inhibitors of the H+/K+ ATP enzyme system, thus affecting acid secretion in the gastric tract (3). The efficacy of numerous PPIs in the treatment of H. pylori infection varies amongst individuals, which may be partially related to variations in the PPI metabolic pathway (4). It has been shown that PPIs are primarily metabolized through CYP450 enzymes, particularly CYP2C19(5). CYP2C19 is highly polymorphic, and >30 variant alleles have been identified (4).
In the Jordanian population, CYP2C19*2 is the principal defective allele (6), which is hypothesized to exhibit reduced enzymatic activity. A previously discovered defective allele for the CYP2C19 enzyme was CYP2C19*17, which is associated with increased enzymatic activity (7). A total of 4 phenotypes have been identified on the basis of PPI metabolism: Ultra-rapid metabolizers (homozygous and heterozygous for the mutant type, CYP2C19*17) (8), extensive metabolizers (homozygous for the wild type, CYP2C19*1), intermediate metabolizers [heterozygous; carrying one mutant allele (CYP2C19*2) and one wild type allele (CYP2C19*1)] and poor metabolizers (homozygous for the mutant type, CYP2C19*2) (4). There is no information available regarding the effect of the CYP2C19 genotype on the eradication of H. pylori amongst the Jordanian population to the best of our knowledge. Therefore, the aims of the present study were to determine the genotype and allele frequencies of CYP2C19*2 and CYP2C19*17 polymorphisms amongst Jordanian patients infected with H. pylori, and to determine whether there was a relation between these genetic polymorphisms and a patient's response to eradication therapy against H. pylori.
This study was conducted in The Gastrointestinal Unit of The University of Jordan Hospital. Every patient provided signed informed consent to participate in this study. The study and the consent form were approved by the Institutional Review Board of The University of Jordan Hospital. Patients who had been diagnosed with H. pylori were interviewed after the completion of the endoscopy procedure, and the information related to each patient was recorded. Patients with H. pylori infection received either triple therapy or sequential therapy as shown in Table SI.
Study cohort
The study population were patients diagnosed with H. pylori infection using a Serim PyloriTek® Test kit (Serim Research Corporation) during the endoscopic procedure. The required sample size was calculated to be ~136 subjects, based on information from previous studies amongst Jordanians and using the Cochran's formula (9). In total of 230 H. pylori infected patients, without serious comorbidities, visited The University of Jordan Hospital in the previous year, according to the records of The Jordan University Hospital. It was calculated that a sample size of 139 patients would represent the H. pylori infected patients attending The University of Jordan Hospital using the power of test 1-β = 0.8, 5% margin of error, and 95% confidence level.
The inclusion criteria of the patients were Jordanians aged between 17-75 years old who had a positive result on the Serim PyloriTek® Test. The exclusion criteria of the patients were: Patients with serious comorbidities, pregnant women, patients allergic to the amoxicillin, metronidazole or lansoprazole, and patients on other PPIs, such as omeprazole.
Accordingly, 149 patients were included in this study, 53.7% were females (n=80) and 46.3% were males (n=69)
The age range of the patients was 17-73 years. Blood samples were collected from 141 patients and a stool test was obtained from 71 subjects. However, 17 patients were excluded from this study for the following reasons: 8 patients did not receive the chosen treatment regimens, and another 9 patients did not complete the treatment regimen.
Blood sample collection and extraction of genomic DNA
From each patient, 3-5 ml whole venous blood was collected in EDTA tubes and stored at 4˚C. DNA was extracted from the whole blood using commercial kits for genomic DNA extraction (Wizard Genomic DNA Purification kit; Promega Corporation), according to manufacturer's protocol.
Genotyping of CYP2C19*2 (681G>A, rs42442850), CYP2C19*17 (-806C>T, rs12248560) alleles
Amplification of specific sites in the CYP2C19 gene containing the genetic variants of interest, CYP2C19*2 and CYP2C19*17, was performed as described by previously (10). The PCR condition were as follows: 200 ng extracted genomic DNA was amplified in a 20 µl reaction volume containing 0.5 mM MgCl2, 1X Taq polymerase buffer (New England Biolabs, Inc.), 0.1 mM dNTPs, 15 pmoles each of the forward and reverse primers (Integrated DNA Technologies, Inc.), and 0.7 unit Taq DNA polymerase (New England Biolabs, Inc.). The thermocycling conditions were 94˚C for 5 min; followed by 35 cycles of denaturation at 94˚C for 45 sec, annealing at 55˚C for 30 sec, and elongation at 72˚C for 40 sec. The primer sequences were: CYP2C19*17 variant forward, 5'-AAATTTGTGTC TTCTGTTCTCAATG-3' and reverse, 5'-AGACCCTGGGAGAACAGGAC-3'; and CYP2C19*2 variant forward, 5'-CAGAGCTTGGCAATATTG TATC-3' and reverse, 5'-ATACGCAAGCAGTCACATAAC-3'.
The PCR products were digested by SmaI restriction enzyme (New England Biolabs, Inc.) at 25˚C for 1 h for identification of the CYP2C19*2 allele. The PCR products were also incubated with the NsiI restriction enzyme (New England Biolabs, Inc.) at 37˚C overnight to detect the CYP2C19*17 allele (10).
The PCR products were separated on 1.5% agarose gel by applying an 125 A current for 20 min. The gel was stained by the Redsafe dye (Intron Biotechnology, Inc.).
Stool sample collection
Each patient was asked to bring a stool sample ≥1 month after completion of eradication therapy, this was used to determine whether the treatment for H. pylori infection had been successful. A positive result indicated a failure of the treatment and a negative result indicated success.
This test was performed using the Wondfo One Step H. pylori Feces Test (Wondfo, China; cat. no. WO6381115), according to the manufacturer's protocol. Briefly, the test kit contained a combination of H. pylori antibody coated particles and anti-mouse IgG antibody to qualitatively and selectively detect H. pylori antigens in stool samples. In the test line region of the kit, H. pylori antibody was immobilized. After the addition of the specimen into the test kit, the specimen was absorbed into the kit and mixed with the antibody-dye conjugate.
Normally distributed continuous variables, such as age, were analyzed using ANOVA followed by a Tukey's HSD post-hoc test. A Pearson's χ2 and Fisher's exact test were used for independent variables to determine the association between CYP2C19*2 and CYP2C19*17 polymorphisms and response to eradication therapy, comparison between sequential and triple therapy, the association between response to eradication therapy and phenotypes.
P<0.05 was considered to indicate a statistically significant difference. Odds ratios for significant association were given with a 95% confidence interval. All statistical analyses were performed using SPSS Inc. version 23 (IBM Corp.).
Genotype frequency of G681A and C-806T polymorphisms amongst Jordanians infected with H. pylori
For the CYP2C19 G681A genotype, the wild type genotype GG was seen (data not shown) in 118 patients (83.7%), the heterozygous genotype GA was seen in 23 patients (16.3%) and the homozygous variant genotype AA was not seen in any patient. Regarding the CYP2C19 C-806T genotype, the wild type genotype CC was seen (data not shown) in 79 patients (56%), the heterozygous genotype CT was seen in 53 patients (37.6%), and the homozygous variant genotype TT was seen in 9 patients (6.4%).
Accordingly, the majority of the patients (54.8%) in the present study carried the extensive-metabolizing phenotype followed by the ultra-rapid-metabolizing phenotype (34%), whereas only a small percentage (8.5%) carried the extensive/intermediate-metabolizing phenotype. None of the patients carried the poor metabolizing phenotype.
Response to H. pylori
eradication treatment. The response to eradication treatment of H. pylori was assessed using two methods; a H. pylori stool antigen (HpSA) test and improvement in symptoms after completion of treatment.
Out of 71 patients, 31% did not exhibit eradication of H. pylori and 69% responded to treatment. Follow up with patients was performed for 100 patients who already had symptoms. They were asked about the degree of symptom improvement after completion of treatment. Improvement was classified into three degrees: Complete improvement, partial improvement and no improvement. Out of the 100 patients, 30% exhibited no improvement of symptoms, whereas 70% showed some degree of improvement (27% had partial improvement and 43% had complete improvement). Correlation between the results of the HpSA test and symptoms improvement was performed for 60 patients. It was found that there was a significant association (Pearson's χ2, P=0.013) between the HpSA test result and the degree of symptom improvement. Of the responders, based on the HpSA test, 73.8% showed improvement (partial or complete) of symptoms, and 61.1% of the non-responders showed no improvement of symptoms.
Patients who were infected with H. pylori were treated with either triple therapy or sequential therapy. The efficacy of the two regimens on the eradication of H. pylori based on the HpSA test results and the degree of improvement of symptoms were assessed. Accordingly, there was no significant difference in the efficacy of the two treatment regimens (Fisher's exact test, P>0.05). Amongst the non-responder group, 50% received triple therapy and 50% received sequential therapy, and amongst the responder group, 54% received triple therapy and 46% received sequential therapy. Additionally, there was no significant difference in the efficacy of the two treatment regimens depending on the patients' symptoms (Fisher's exact test, P>0.05). Amongst patients who did not improve, 60% received triple therapy and 40% received sequential therapy. Amongst patients who improved completely, 55.8% received triple therapy and 44.2% received sequential therapy.
Association between the G681A polymorphism and response to eradication therapy
Next, whether there was a relation between the G681A polymorphism and the response to eradication therapy was assessed using the results of the HpSA test and the degree of improvement in symptoms. As shown in Table I, there was no significant difference the two CYP2C19 G681A genotypes GG and GA and the response to eradication therapy, using both the HpSA test and degree of the infections symptoms (Fisher's exact test, P>0.05) between.
Distribution of the G681A genotype amongst responders and non-responders to eradication therapy based on the HpSA test and degree of symptoms.
G681A genotype, n (%)
Method of assessment
P-valuea
HpSA test 0.198
Responder 34 (51.5) 11 (16.7) 45
Non-responder 19 (28.8) 2 (3.0) 21
Total 53 13 66
Reporting of symptoms 0.354
Complete improvement 37 (39.4) 3 (3.2) 40
Partial improvement 21 (22.3) 5 (5.3) 26
No improvement 24 (25.5) 4 (4.3) 28
[i] aFischer's exact test. HpSA, H. Pylori stool antigen.
Association between C-806T polymorphism with response to eradication therapy
No significant difference was found between the CYP2C19 C-806T genotypes CC, CT and TT and response to eradication therapy based on the HpSA and the degree of symptoms (Fisher's exact test, P>0.05; Table II).
Distribution of the C-806T genotype amongst responders and non-responders to eradication therapy based on HpSA test and the degree of symptoms.
C-806Tgenotype, n (%)
Responder 30 (45.5) 14 (21.2) 1 (15.0) 45
Non-responder 15 (22.7) 5 (7.6) 1 (15.0) 21
Total 45 19 2 66
Complete improvement 20 (21.3) 19 (20.2) 1 (1.1) 40
Partial improvement 16 (17.0) 9 (9.5) 1 (1.1) 26
No improvement 20 (21.3) 8 (8.5) 0 (0.0) 28
Distribution of responders and non-responders to H. pylori
eradication amongst the different CYP2C19 phenotypes based on the G681A and C-806T genotypes. The relationship between different CYP2C19 phenotypes and the response to eradication therapy was assessed. There was no significant difference between the different phenotypes of CYP2C19 metabolism and the response to H. pylori eradication based on the results of the HpSA test and the degree of H. pylori infection (Fisher's exact test, P>0.05; Table III).
Distribution of the CYP2C19 phenotype amongst responders and non-responders based on the HpSA test and degree of symptoms.
Het.EM/IM
Het.UM
Responder 29 (44.0) 6 (9.1) 1 (1.5) 9 (13.6) 45
Non-responder 13 (19.7) 2 (3.0) 1 (1.5) 5 (7.6) 21
Total 12 8 2 14 66
Complete improvement 19 (20.2) 2 (2.1) 1 (1.1) 18 (19.1) 40
Partial improvement 11 (11.7) 5 (5.3) 1 (1.1) 9 (9.6) 26
No improvement 20 (21.3) 2 (2.1) 0 (0.0) 6 (6.4) 28
[i] aFischer's exact test. HpSA, H. Pylori stool antigen; EM, extensive metabolizers; IM, intermediate metabolizer; UM, Ultra-rapid metabolizer; Het, heterogenous.
H. pylori infection is a common infection worldwide (1). Eradication of infection should be achieved to prevent further the complications when left untreated (11). All eradication regimens include the administration of PPIs, which play an important role in the treatment of H. pylori (12). However, eradication is not successful in several cases, due to various issues. One such issue is the variation in the metabolism of the PPIs between patients (13). The present study revealed that ~30% of patients receiving the recommended therapy did not achieve eradication. This may be due to numerous factors other than CYP2C19 polymorphisms, such as age, nutritional status, sex, liver and kidney function, and concomitant medications and diseases (14). Several studies examined the effect of CYP2C19 polymorphisms (in particular G681A and C-806T) on the metabolism of lansoprazole; they reported that carriers of the G681A polymorphism exhibit a lower enzymatic capacity to metabolize lansoprazole, and thus, those subjects possess an increased ability to eradicate H. pylori (15,16). Conversely, other studies have reported that carriers of the C-806T polymorphism exhibit increased metabolizing activity of lansoprazole, thus, they are less likely to benefit from the standard dose of lansoprazole (17). However, there are no studies on the effect of these polymorphisms in the eradication of H. pylori infection amongst the Jordanian population. Therefore, the aim of the present study was to investigate the effect of such polymorphisms on the response to eradication regimens. It was shown that there was a difference in the response to eradication therapy between extensive metabolizers (carrying the GG genotype) and intermediate metabolizers (carrying the GA genotype); the majority of patients that did not achieve eradication were extensive metabolizers, not intermediate metabolizers (90.5 vs. 9.5%, respectively). Additionally, amongst the extensive metabolizing individuals, it was shown that 35.8% were non-responders, whereas only 15.4% of the intermediate metabolizing patients were non-responders. However, these results were statistically insignificant. These results are similar to other previous studies where they found no significant effect on CYP2C19 genetic polymorphisms and the PPI response (18,19). These findings however also contradict several other studies that concluded that there was a significant relation between the G681A polymorphism and response to eradication therapy based on lansoprazole (20,21). The difference in the results may be due to the small sample size included in the present study, and differences in ethnicities.
On the other hand, several studies have found similar results of what was observed in the present study (22,23). Although there are controversial results regarding the influence of the CYP2C19 genotype on the effects of PPIs, no association between CYP2C19 genotype and the eradication of H. pylori was observed in the present study. These results suggest that the CYP2C19 genotype is not a potential biomarker for determination of the proton pump response, at least amongst Jordanian patients.
There was no significant difference between the efficacy of the triple regimen and sequential regimen. Amongst non-responders, 50% received the triple regimen and the other 50% received the sequential regimen. Moreover, amongst responders, 54% received the triple regimen, whereas 46% received sequential therapy. Although these findings are in agreement with the findings of Gawrońska-Szklarz et al (23), they conflict with other studies and meta-analyses (24-26), which concluded that there was a significant difference between standard triple therapy and sequential therapy. Those studies showed that the sequential therapy achieved higher eradication rates compared to triple therapy. Regarding the assessment of response after eradication treatment, a significant association existed between the HpSA test results and the degree of symptom improvement; 73.8% of the responders showed improvement (partial or complete) of symptoms, and 61.1% of the non-responders showed no improvement of symptoms.
The frequency of the 681A mutant allele in Jordanian patients infected with H. pylori was found to be 8.2%. The mutant 681A allele frequency within different populations ranged from 7.8 to 45.5%. 681A allele frequency amongst several populations was similar to the Jordanian, including Russian (27), Italian (28), Norwegian (29), Egyptian (30) and Ethiopian (8) cohorts. Conversely, several other populations, including Faroese (31), Danish (31), African Americans (32). Chinese (33), Korean (34) and Japanese (10) showed significant differences in G681A allele frequencies compared with the Jordanian patients infected with H. pylori. Regarding the variant allele -806T, the frequency was found to be 25.2% in the present study population. This was similar to the allele frequency of Faroese (31), Danish (31), African American (32) and Norwegian (29). However, Chinese (8), Korean (34) and Japanese (10) showed a difference in the -806 allele frequency compared with the present study.
One of the limitations of the present study is the relatively small sample size of the H. pylori infected patients, which resulted in a lack of patients with a poor CYP2C19 metabolizer phenotype. This may result in a bias in the conclusions drawn regarding the influence of the CYP2C19 genotype on the response to lansoprazole. Further studies with larger cohorts of Jordanian patients are required to confirm the findings of the present study. In addition, this study did not investigate the association of CYP2C19 genotype with the patients morbidity and complications secondary to H. pylori infection. These clinical factors will be taken into consideration in the future studies regarding the influence of CYP2C19 genotype on lansoprazole response.
In conclusion, there was no significant association found between the CYP2C19 G681A and C-806T polymorphisms and the response to eradication therapy amongst Jordanian patients infected with H. pylori.
Prescribed treatment regimens for Helicobacter pylori eradication.
The authors would like to thank Deanship of Scientific Research, The University of Jordan for supporting this research.
This research was funded by the Deanship of Scientific Research, The University of Jordan (grant no. 21/2014/2015).
BB conducted the experimental work. MR and ZA contributed to the clinical evaluation and analysis of the patients. BB, MZ and YJ analyzed the data. MZ and BB wrote this manuscript and YJ revised it. Αll authors have read and approved the final manuscript.
Every patient provided signed informed consent to participate in this study. The study and the consent form were approved by the Institutional Review Board of The University of Jordan Hospital (Amman, Jordan).
Malaty HM and Nyren O: Epidemiology of Helicobacter pylori infection. Helicobacter. 8 (Suppl 1):8–12. 2003.PubMed/NCBI View Article : Google Scholar
Chey WD and Wong BC: Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 102:1808–1825. 2007.PubMed/NCBI View Article : Google Scholar
Shin JM and Sachs G: Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 10:528–534. 2008.PubMed/NCBI View Article : Google Scholar
Lee SJ: Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine. Front Genet. 3(318)2013.PubMed/NCBI View Article : Google Scholar
Ishizaki T and Horai Y: Review article: Cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole. Aliment Pharmacol Ther. 13 (Suppl 3):27–36. 1999.PubMed/NCBI View Article : Google Scholar
Zalloum I, Hakooz N and Arafat T: Genetic polymorphism of CYP2C19 in a Jordanian population: Influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole. Mol Biol Rep. 39:4195–4200. 2012.PubMed/NCBI View Article : Google Scholar
Li-Wan-Po A, Girard T, Farndon P, Cooley C and Lithgow J: Pharmacogenetics of CYP2C19: Functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol. 69:222–230. 2010.PubMed/NCBI View Article : Google Scholar
Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L and Ingelman-Sundberg M: A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 79:103–113. 2006.PubMed/NCBI View Article : Google Scholar
Charan J and Biswas T: How to calculate sample size for different study designs in medical research? Indian J Psychol Med. 35:121–126. 2013.PubMed/NCBI View Article : Google Scholar
Sugimoto K, Uno T, Yamazaki H and Tateishi T: Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population. Br J Clin Pharmacol. 65:437–439. 2008.PubMed/NCBI View Article : Google Scholar
Dowdle WR: The principles of disease elimination and eradication. Bull World Health Organ. 76 (Suppl 2):22–25. 1998.PubMed/NCBI
Yang JC, Lu CW and Lin CJ: Treatment of Helicobacter pylori infection: Current status and future concepts. World J Gastroenterol. 20:5283–5293. 2014.PubMed/NCBI View Article : Google Scholar
Mégraud F and Lamouliatte H: Review article: The treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 17:1333–1343. 2003.PubMed/NCBI View Article : Google Scholar
Jarrar Y and Lee SJ: The functionality of UDP-Glucuronosyltransferase genetic variants and their association with drug responses and human diseases. J Pers Med. 11(11)2021.PubMed/NCBI View Article : Google Scholar
Kuo CH, Lu CY, Shih HY, Liu CJ, Wu MC, Hu HM, Hsu WH, Yu FJ, Wu DC and Kuo FC: CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol. 20:16029–16036. 2014.PubMed/NCBI View Article : Google Scholar
Zhao F, Wang J, Yang Y, Wang X, Shi R, Xu Z, Huang Z and Zhang G: Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: A meta-analysis. Helicobacter. 13:532–541. 2008.PubMed/NCBI View Article : Google Scholar
Shirasaka Y, Chaudhry AS, McDonald M, Prasad B, Wong T, Calamia JC, Fohner A, Thornton TA, Isoherranen N, Unadkat JD, et al: Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content. Pharmacogenomics J. 16:375–387. 2016.PubMed/NCBI View Article : Google Scholar
Miki I, Aoyama N, Sakai T, Shirasaka D, Wambura CM, Maekawa S, Kuroda K, Tamura T, Kita T, Sakaeda T, et al: Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. Eur J Gastroenterol Hepatol. 15:27–33. 2003.PubMed/NCBI View Article : Google Scholar
Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Inaba T, Yamamoto K, Okada H, Yokota K, Oguma K, et al: Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2019 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection. Am J Gastroenterol. 98:2403–2408. 2003.PubMed/NCBI View Article : Google Scholar
Kawabata H, Habu Y, Tomioka H, Kutsumi H, Kobayashi M, Oyasu K, Hayakumo T, Mizuno S, Kiyota K, Nakajima M, et al: Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. Aliment Pharmacol Ther. 17:259–264. 2003.PubMed/NCBI View Article : Google Scholar
Okudaira K, Furuta T, Shirai N, Sugimoto M and Miura S: Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19. Aliment Pharmacol Ther. 21:491–497. 2005.PubMed/NCBI View Article : Google Scholar
Kurzawski M, Gawrońska-Szklarz B, Wrześniewska J, Siuda A, Starzyńska T and Droździk M: Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur J Clin Pharmacol. 62:877–880. 2006.PubMed/NCBI View Article : Google Scholar
Gawrońska-Szklarz B, Siuda A, Kurzawski M, Bielicki D, Marlicz W and Droździk M: Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole. Eur J Clin Pharmacol. 66:681–687. 2010.PubMed/NCBI View Article : Google Scholar
Park HG, Jung MK, Jung JT, Kwon JG, Kim EY, Seo HE, Lee JH, Yang CH, Kim ES, Cho KB, et al: Randomised clinical trial: A comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients. Aliment Pharmacol Ther. 35:56–65. 2012.PubMed/NCBI View Article : Google Scholar
Choi HS, Chun HJ, Park SH, Keum B, Seo YS, Kim YS, Jeen YT, Um SH, Lee HS, Kim CD, et al: Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection. World J Gastroenterol. 18:2377–2382. 2012.PubMed/NCBI View Article : Google Scholar
Liou JM, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, Lee JY, Hsu SJ, Luo JC, Chang WH, et al: Taiwan Helicobacter Consortium: Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: A multicentre, open-label, randomised trial. Lancet. 381:205–213. 2013.PubMed/NCBI View Article : Google Scholar
Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmöller J, Frötschl R, Köpke K, Gerloff T, Chernov JN and Roots I: Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol. 59:303–312. 2003.PubMed/NCBI View Article : Google Scholar
Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E and Ingelman-Sundberg M: Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol. 52:447–450. 2001.PubMed/NCBI View Article : Google Scholar
Rudberg I, Mohebi B, Hermann M, Refsum H and Molden E: Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther. 83:322–327. 2008.PubMed/NCBI View Article : Google Scholar
Hamdy SI, Hiratsuka M, Narahara K, El-Enany M, Moursi N, Ahmed MS and Mizugaki M: Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol. 53:596–603. 2002.PubMed/NCBI View Article : Google Scholar
Pedersen RS, Brasch-Andersen C, Sim SC, Bergmann TK, Halling J, Petersen MS, Weihe P, Edvardsen H, Kristensen VN, Brøsen K, et al: Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: Identification of CYP2C haplotypes in healthy Nordic populations. Eur J Clin Pharmacol. 66:1199–1205. 2010.PubMed/NCBI View Article : Google Scholar
Bravo-Villalta HV, Yamamoto K, Nakamura K, Bayá A, Okada Y and Horiuchi R: Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: An investigative and comparative study. Eur J Clin Pharmacol. 61:179–184. 2005.PubMed/NCBI View Article : Google Scholar
Chen L, Qin S, Xie J, Tang J, Yang L, Shen W, Zhao X, Du J, He G, Feng G, et al: Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China. Pharmacogenomics. 9:691–702. 2008.PubMed/NCBI View Article : Google Scholar
Lee SJ, Kim WY, Kim H, Shon JH, Lee SS and Shin JG: Identification of new CYP2C19 variants exhibiting decreased enzyme activity in the metabolism of S-mephenytoin and omeprazole. Drug Metab Dispos. 37:2262–2269. 2009.PubMed/NCBI View Article : Google Scholar
Supplementary_Data.pdf


text:
Bornkamp Dubbed As United Soccer Coaches All-American
Clemson, S.C. – Freshman Megan Bornkamp became the 19th All-American in program history and first since Sam Staab in 2018, being named to the 2020-21 United Soccer Coaches Third Team All-America on Thursday afternoon.
Of the 50 student-athletes selected across the three All-America teams, the Mooresville, N.C native is just one of two freshmen to earn the status this season, joining Lia Godfrey of Virginia.
"Obviously it is a wonderful accolade for Megan and it is fully deserved," said Head Coach Eddie Radwanski. "For a freshman to come in and help and impact the team the way she did is a credit to her. She has this drive and desire to try and be the best so this is just a small step for what's to come for her but it is nice to see other coaches have recognized what she brings to a team. Individually, I am happy for Megan as she has a great passion for the game – you love to see players get rewarded for that."
Netting a team-leading eight goals in 2020-21, four of those coming as game-winners, Bornkamp solidified herself as one of the top players in the league, leading all Atlantic Coast Conference freshmen for goals this season. Among her eight goals, the freshman tallied multi-goal games on two separate occasions.
Playing and starting in all 19 games, Bornkamp led the team with nearly 1,700 minutes of action. She had previously earned a spot on the ACC All-Freshman and Third Team this fall.


All parts within the Hot Horse Showers are available as spare parts.
We've listed the most commonly required ones, but if you need any other part please enquire.
This is the replacement Water/gas kit for the Hot Horse Shower. If your shower has frozen this is the part that most likely needs replacing. It comes as a kit and bolts into place.
Please make sure you choose the correct model for the model of shower that you have.
We recommend you employ an LPG qualified Gas Safe registered gas fitter to carry out this work.
Water micro switch assembly. Includes the probe that fits into the brass gas/water kit and seal.
Please make sure you choose the correct model part for the model of Hot Horse Shower that you have.
This is the replacement solonoid/gas valve for the Hot Horse Showers.
Choose the correct option for the model of Hot Horse Shower that you have.
Please choose the correct option for the model of Hot Horse Shower that you have.
Please select the postage option for a small item at check out.
This is the replacement reconditioned water kit for the Hot Horse Shower Supreme 11B. If your shower has frozen this is the part that most likely needs replacing. It comes as a kit and bolts into place.
Gas connection kit. 37mBar Propane gas regulator, 1m flexible hose and threaded brass connector including neoprene washer. Make sure the washer is in place before connecting to heater unit.
Important: Read the fitting instructions BEFORE connecting and before using the appliance.
Postage: please choose the £5.00 "small part" postage option at checkout.
Replacement multi pattern spray gun.
High quality alloy and plastic with soft feel rubberised hand grip. Choice of spray patterns including soaker, shower, jet, flat spray, cone.


Ticino is classically designed collection from Picard & Wielpütz featuring teardrop handles to suit both casual and formal table settings. A 24-piece service set for four.
For more than 90 years Picard & Wielpütz has been producing high quality table cutlery in Solingen, Germany. The company has maintained the tradition of Solingen by producing commercial quality flatware widely used in hotels and restaurants in Europe.


text:
Datasets without APIs (6)
MAPVIEWER (4)
Heritage Council (4)
Theme: Economy Resource Format: XLS
Museum Standards Programme for Ireland
MAPVIEWER
The Heritage Council's main commitment to collections care comes through its support of the Museum Standards Programme for Ireland (MSPI). This important initiative, with participants from a wide range of Irish collecting institutions, sets out to raise standards of care...
Museums Collections Archives
Museums, Collections and Archives dataset created and managed by the Heritage Council. This dataset is a comprehensive record of natural and cultural heritage facilities open to the public across the island of Ireland. The dataset was created to provide a comprehensive list of...
Irish Landmark Trust
The Irish Landmark Trust, since 1992, have been saving some of Ireland's most iconic buildings, and making them accessible to the wider community. We restore properties sensitively, with a focus on best practices in conservation, as well as comfort for our guests. An Irish...
Local Authority Museums Network
The Local Authority Museums Network dataset created by the Heritage Council.This dataset maps, and provides details for, the Local Authority-run County museums across Ireland.
Voted Public Expenditure
Department of Public Expenditure and Reform
The Public Expenditure Databank provides access to a comprehensive set of data on voted public expenditure in Ireland. The figures reflected in the databank detail all current and capital spending by Government Departments and agencies, along with expenditure from the Social...
Public Service Numbers 1980-2015
The Public Service Numbers databank provides access to a comprehensive set of Public Service Numbers presented on a whole time equivalent basis and shows the numbers of staff employed in each sector for the period 1980 to 2015. From 1980 to 2007 the end quarter Q4 figures are...


Good Friday, April 19 - Easter Monday, April 22 - Liberation Day, Thursday April 25 - Labour Day, Wednesday May 1.
Acne Studios awarded the 2017 Cultural and Creative Industries Export Prize.
The Embassy of Sweden has moved.
Renewal of Swedish passport, consular issues and fees. Information available only in Swedish or Italian language.
Working in Sweden, travel to Sweden, study in Sweden or just interested in Sweden.


text:
The Vanity Serum () is a 2004 Italian giallo film directed by Alex Infascelli. It is loosely based on the novel Il libro italiano dei morti by Niccolò Ammaniti.

Plot synopsis
The VIPs of Italian television mysteriously disappear. Two detectives, Lucia and Franco, try to investigate the mystery, drowning into a strange world ruled by the powerful movie star Sonia Norton.

Cast
Margherita Buy as Lucia Allasco
Francesca Neri as  Sonia Norton
Valerio Mastandrea as  Franco Berardi
Barbora Bobuľová as  Azzurra Rispoli
Marco Giallini as  Michele Benda
Ninni Bruschetta as  Vittorio Terracciano
 Luis Molteni as  Rocco Piccolo
 Rosario J. Gnolo  as  Mago Daniel
 Armando De Razza as  Michel Simone

See also
 List of Italian films of 2004

References

External links

2004 films
Giallo films
Films directed by Alex Infascelli
2000s mystery films
1990s Italian films

redpajama_set_name: RedPajamaWikipedia


text:
CANYON OF THE SKULL Pay It Forward Via 'Sins Of The Past' Album Arrival
October 22, 2019 Pat 'Riot' Whitaker
Article By: Pat 'Riot' Whitaker, Senior Writer/Journalist ‡ Edited By: Leanne Ridgeway, Owner/Editor
CANYON OF THE SKULL from The Windy City of Chicago, Illinois are set to unleash their third studio album, 'Sins Of The Past', on November 20th.
In the span of its two lengthy, utterly epic tracks, the instrumental trio effectively conjure forth a beast of blackened heavy metal and doom. This is immediately recognized upon hearing the first song initiating the album, "The Ghost Dance". This 25 minute-plus composition is a sinister, soul dissecting, slow campaign laden with oppressive doom elements and terror inducing undercurrents.
Streaming at this time, "The Ghost Dance" is accompanied by the 'Sins Of The Past' album artwork and other particulars. The album's artwork, layout, and design was done by Erik Bredthauer. Guitarist Erik Ogershok had the following to offer about CANYON OF THE SKULL and their latest offering saying:
"I try to do different things with each record and this one is no exception. This record is visceral and immediate, like the self-titled, while being highly conceptual and dynamic like 'The Desert Winter'. 'The Ghost Dance' is probably the best thing that I have written to date. 'The Sun Dance' is unlike anything that I have ever written before. It incorporates my basic philosophies of composition but applies them differently, one that I jokingly call prog-doom.
The main aesthetic and themes that Canyon Of The Skull was founded on remain unchanged. This band has always been focused on telling the stories of Indigenous Americans and their environments, specifically those of the American Southwest. I am still surprised at how many people have never met an Indigenous American, but we are not extinct, and this band exists to tell our stories both past, present, and future. This record is a bit more broad with the subject matter since it involves the rituals of tribes far from the land of my people. Also, this record is more influenced by recent events that have an impact beyond Native communities. I don't like to talk specifically about the deeper meaning of any of my compositions as I want people to discover their meaning in our music. These two pieces have very specific meanings to both me and the wider world and googling the titles is my recommendation for people that want to delve deeper for the literal meanings."
Founded by Erik Ogershok in 2006, the initial version of CANYON OF THE SKULL played many live shows and recorded a demo before career demands forced Erik to reevaluate things as a band. He then continued to release music as a one-man project for several years, before fate intervened once again and a multiple member band manifested itself. Releasing two previous offerings in 2017's 'The Desert Winter', and 2015's self-titled 'Canyon Of The Skull', it would not be until 2018 that this act found its most formidable line up yet.
Relocating to Chicago that year, Erik soon recruited close friend Todd Haug (Powermad) as bassist, and Mike Miczek (Broken Hope, The Atlas Moth, Powermad) as the drummer for the band. Now, a mere few months after that galvanizing embrace resulted in the evolution to becoming a trio, CANYON OF THE SKULL stand poised to impress with their imminent album delivery.
'Sins Of The Past' was recorded, produced, and mixed by Sanford Parker at Decade Music Studios in March 2019, with mastering by Collin Jordan at Boiler Room Mastering. It will arrive November 20th and pre-order is available HERE.
01. The Ghost Dance
02. The Sun Dance
Copyright secured by Digiprove © 2019All Rights Reserved
2019, Album Art, Audio Stream, Bandcamp, Boiler Room Mastering, Canyon Of The Skull, Decade Music Studios, Doom, Illinois, Instrumental, Psychedelia, Sludge, Streaming
About Pat 'Riot' Whitaker
Formerly known as Dragon so you probably already know my deal. METAL & ROCK! Nearly 40 years involved in it, every style, genre & sub genre you can imagine. I'm as real as it gets... come put me to the test.
View all posts by Pat 'Riot' Whitaker →
Oldschool Sunday: HAWK
OYSTERHEAD (Primus, The Police, Phish) 2020 Reunion Shows Announced
WEEDEATER U.S. Tour w/ The Goddamn Gallows; The Atomic Bitchwax, Worshipper, & Left Lane Cruiser


Let's face it. When it comes to buying weed, most of us are still in the novice category.
The oldest recreational stores have only been open for about two years, and even medical marijuana patients – who have been buying legal pot for a bit longer than that – sometimes don't know what to look for when they venture in looking to make a purchase.
To help, I thought I'd put together a list of things I look for when weed shopping. I'm a medical patient and often seek out certain products for my ailments, but I also love to support the local legal recreational (fun) shops.
Scouting Report: First and foremost, I look up cannabis shops in my area before visiting them. I like to check out their online menus and see what their all-around vibe is. I do this for three reasons: To have an idea of what's available; to do my own strain research beforehand in case the budtenders are busy; and to check out the prices. Prices vary quite a bit at different stores, and I like to figure out which shop has what I want at a price I can afford. Thanks to websites like Leafly and Weedmaps, it's easy to find local shops and menus. Instagram, Facebook, and Twitter are also good places to find shops, and they often use them to tell you about specials and price drops.
Prices: You never want to overpay for weed, and let's be real, some of us don't even have that luxury. That's why price is an important thing to keep in mind. All shops have a variety of different types of cannabis: low, mid and top shelf product at a range of prices. Medical weed is less expensive (usually you don't have to pay tax on it). Recreational prices in Portland and Washington are a bit higher due to sales tax, so keep that in mind. Generally in both states recreational after-tax prices range from $8 for the cheap stuff to about $17 for top shelf. And if you keep your eye out for deals on social media, you might find some even better deals than that.
Quality/Look: In the almost 2 years of being a medical patient, I've visited A LOT of shops and let me tell you, not all shops care about the quality of the product they're putting out – that goes for both medical and recreational shops. If I know a shop doesn't care about bud quality, I won't return. You want your buds to be dense, well-trimmed (without a lot of leafy material) and well cured. I think if you're a business selling something as precious as cannabis, you need to care about the quality of product whether it's top shelf or "budget" weed. Not all cannabis customers are privy to smelling a giant, open jar full of deliciously smelling weed to sway them into a purchase, so for those who can only decide by staring at the product in a plastic bag, do your best to study the appearance of the bud to figure out whether it's worth your hard earned cash.
Budtenders/Service: Budtenders are the ambassadors of the chronic palaces that we call weed shops, it's their duty to educate customers on the products they sell and how they work. When you need information on strains, concentrates or topicals, budtenders are the people who should have all the answers for you. Your budtender also gets extra points if they remember who you are and what you like – and if you find one with good suggestions, you should keep going back. It's important to feel like the business you're spending your money at cares about you as a consumer (or as a patient) and your experience with them and their products. Customer service is the best way for stores to get repeat customers, but keep in mind that budtenders do get busy. I had one bad experience at a shop and I would say the blame fell on both of us. On the store side, the employees didn't care that I was standing there with unanswered questions, but on the other hand, I didn't make it a point to let them know I needed assistance. If you're unsure of what type of service you should be getting, I urge you to check out the Budtender's Bible, a guide for budtenders, but something consumers should be privy to as well.
Always remember, every experience is different and no cannabis shops are the same, but if you keep an eye out for quality product and people – you won't be disappointed.